Researchers in Germany have discovered that mitoxantrone-used to treat aggressive, relapsing, or progressive multiple sclerosis-can increase the risk of leukemia and colorectal cancer in those being treated.
Following a median follow-up of more than 8 years, researchers in Germany have discovered that mitoxantrone—used to treat aggressive, relapsing, or progressive multiple sclerosis (MS)—can increase the risk of leukemia and colorectal cancer (CRC) in those being treated.
Published in the journal Neurology, the authors of the study conducted by researchers at the
University of Würzburg in Germany, retrospectively observed 677 patients who were administered mitoxantrone for their MS, between 1994 and 2007. Follow-up data, gathered till 2010 for 676 patients, included malignancies, life status, and cause of death.
During the median follow-up period of 8.7 years (interquartile range, 6.8-11.2), 37 patients were diagnosed with a malignancy: either breast cancer (9 patients), CRC (7 patients), acute myeloid leukemia (AML, 4 patients), or other (1 or 2 patients). Following a comparison with the German national cancer registry, the authors reported standardized incidence ratio of CRC at 2.98 (95% CI, 1.20-6.14) and of AML 10.44 (95% CI, 3.39-24.36). Of the reported 55 deaths, 12 patients died of a malignancy.
Risk factors, the authors found, included age at treatment initiation as a significant risk factor for developing malignancies. Sex, cumulative dose of mitoxantrone, or treatment with other immunosuppressive agents did not seem to play a role in increasing the patient’s risk of developing a malignancy.
Explaining the significance of their findings, lead author Mathias Buttmann, MD, of the University of Würzburg, said in a statement, “Despite an increased risk of acute myeloid leukemia and colorectal cancer, the overall rate of cancer was low enough to justify still using this drug for people severely affected by MS if no better treatment is available. Mitoxantrone is the only approved treatment for people with secondary progressive MS without relapses and should be considered in people where the disease is evolving quickly. Also, many of the new and highly effective MS drugs are not available to people in a number of countries for economic reasons, so mitoxantrone is being used for people with very active relapsing forms of the disease.”
Citing the small sample size of their study as a limitation, Buttmann advised that additional studies are needed to confirm their findings. He also recommended that if their results are confirmed, patients being treated with mitoxantrone should undergo colonoscopy so they would be diagnosed earlier.
Reference
Buttmann M, Seuffert L, Mäder U, Toyka KV. Malignancies after mitoxantrone for multiple sclerosis [published online May 11, 2016]. Neurology. doi:http:/​/​dx.​doi.​org/​10.​1212/​WNL.​0000000000002745.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More